Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
Nathan Fowler(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Veerabhadran Baladandayuthapani(The University of Texas MD Anderson Cancer Center), Tariq Muzzafar(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Peter McLaughlin(The University of Texas MD Anderson Cancer Center), Seema Rawal(The University of Texas MD Anderson Cancer Center), Yasuhiro Oki(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Robert Z. Orlowski(University of North Carolina at Chapel Hill), Kenneth Y. Tsai(Moffitt Cancer Center), Lei Feng(Shandong Tumor Hospital), R. Eric Davis(National Institutes of Health), Linda Claret(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Michelle A. Fanale(The University of Texas MD Anderson Cancer Center), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), Michael Wang(The University of Texas MD Anderson Cancer Center), Francesco Turturro(The University of Texas MD Anderson Cancer Center), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center), Jatin J. Shah(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center)
Cited by 263
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k